The Cell & Gene Therapy (CGT) market is expected to reach sales of $76.03 billion by 2030 and play a significant role in 2025, with innovative payment models emerging to address its high costs. CMS’s CGT Access Model aims to improve access to CGTs for Medicaid beneficiaries through outcomes-based agreements, starting with sickle cell disease. Through the employer lens, the high cost of CGT has employers fearful of the financial implications to their health plans.